---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-26-001597"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2026-03-23T23:59:59+00:00"
generated_at: "2026-05-15T09:25:26.899090+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Silexion Therapeutics shareholders vote down share capital increase and equity plan expansion

## Summary
- At reconvened EGM on March 23, 2026, quorum met with 1,216,369 shares (36.6% of outstanding).
- Proposal to increase authorized shares from 9M to 59M failed: 38.2% for, 61.8% against.
- Proposal to expand evergreen provision of 2024 equity plan to 10% fully diluted failed: 40.7% for, 59.3% against.
- Neither proposal received the simple majority required for approval.

## SEC filing metadata
- accession: 0001178913-26-001597
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2026-03-23T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891326001597/0001178913-26-001597-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891326001597/zk2634902.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-26-001597
- JSON: https://secwatch.observer/filing/0001178913-26-001597.json
- Plain text: https://secwatch.observer/filing/0001178913-26-001597.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.